EPS for Amicus Therapeutics, Inc. (FOLD) Expected At $-0.36

April 22, 2018 - By Max Morgan

Amicus Therapeutics, Inc. (NASDAQ:FOLD) LogoInvestors sentiment decreased to 1.21 in 2017 Q4. Its down 1.12, from 2.33 in 2017Q3. It dived, as 25 investors sold Amicus Therapeutics, Inc. shares while 48 reduced holdings. 25 funds opened positions while 63 raised stakes. 197.59 million shares or 2.54% more from 192.70 million shares in 2017Q3 were reported.
Trexquant Invest L P holds 25,261 shares or 0.04% of its portfolio. Rockefeller Fincl Ser holds 19,169 shares. Fortaleza Asset, Illinois-based fund reported 7,215 shares. Tower Capital Limited Liability Corp (Trc) holds 944 shares. Amalgamated Bankshares stated it has 22,766 shares or 0.01% of all its holdings. Moreover, Public Employees Retirement Association Of Colorado has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Raymond James owns 192,978 shares for 0.01% of their portfolio. Hanseatic Mngmt holds 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 60 shares. Spark Investment Mgmt Limited Liability Com holds 0.21% or 270,900 shares in its portfolio. Wells Fargo Mn owns 771,905 shares or 0% of their US portfolio. Prudential Fincl holds 599,610 shares. Credit Suisse Ag reported 685,841 shares. Moreover, First Midwest Retail Bank Division has 0.12% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Pointstate Capital Lp holds 1.09 million shares. Minnesota-based Us Bancorp De has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Since December 11, 2017, it had 3 buys, and 17 sales for $3.94 million activity. 32,500 shares valued at $517,371 were sold by Campbell Bradley L on Monday, January 22. The insider Do Hung sold 50,000 shares worth $750,000. Quimi Daphne sold 8,149 shares worth $114,537. $72,058 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares were sold by RAAB MICHAEL. $300,002 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by HAYDEN DONALD J JR. PERCEPTIVE ADVISORS LLC bought $4.55M worth of stock or 335,827 shares.

Analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report $-0.36 EPS on May, 8.They anticipate $0.03 EPS change or 7.69 % from last quarter’s $-0.39 EPS. After having $-0.41 EPS previously, Amicus Therapeutics, Inc.’s analysts see -12.20 % EPS growth. The stock decreased 2.94% or $0.43 during the last trading session, reaching $14.21. About 1.61 million shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 90.40% since April 22, 2017 and is uptrending. It has outperformed by 78.85% the S&P500.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Among 2 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Amicus Therapeutics had 2 analyst reports since February 8, 2018 according to SRatingsIntel. Robert W. Baird maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Wednesday, February 7 with “Buy” rating. The firm has “Outperform” rating given on Thursday, February 8 by Leerink Swann.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company has market cap of $2.67 billion. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. It currently has negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: